Analystreport

Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $35.00 price target on the stock.

Revance Therapeutics, Inc.  (RVNC) 
Last revance therapeutics, inc. earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.revance.com